



## **Maze Therapeutics Expands Experienced Management Team with Appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer**

**SOUTH SAN FRANCISCO, Oct. 6, 2020** –Maze Therapeutics, a company focused on translating genetic insights into new medicines, today announced that Sarah Noonberg, M.D., Ph.D., has been appointed as the company’s chief medical officer. Dr. Noonberg brings significant industry and clinical experience to Maze as the company works to advance its pipeline.

“Sarah is an exceptional leader who has helped guide multiple companies through various stages of clinical development and commercialization, and we are thrilled to welcome her to the Maze team,” said Jason Coloma, Ph.D., chief executive officer of Maze. “We have been working hard to build an exciting pipeline of potential therapeutics based on targets generated through our platform, and Sarah’s broad experience leading programs from translational research through commercialization for both rare and common diseases will be instrumental. As we take important steps toward entering the clinic and defining our development strategies, we could not be more excited to have her on board and for the future of Maze.”

Dr. Noonberg is a board-certified physician-scientist with broad expertise and a proven track record in global clinical development and corporate strategy. Dr. Noonberg joins Maze from prior roles as chief medical officer of Nohla Therapeutics and Prothena Biosciences, and earlier, head of global clinical development at BioMarin Pharmaceutical, Inc., where she advanced a broad portfolio including cerliponase alfa (Brineura™) for CLN2 disease, pegvaliase (Palyngiq™) for phenylketonuria, and gene therapy for hemophilia A. Prior to BioMarin, she was senior vice president at Medivation leading translational and early development activities as well as late-stage development of enzalutamide (XTANDI™) for advanced prostate cancer. Dr. Noonberg currently serves on the board of directors of Protagonist Therapeutics and Neoleukin Therapeutics. She holds an M.D. from the University of California, San Francisco, a Ph.D. in bioengineering from the University of California, Berkeley, and a B.S. in engineering science from Dartmouth College.

“Maze has assembled all of the key ingredients to produce a diverse pipeline of meaningful therapeutics that could significantly impact the treatment of patients with a broad range of diseases,” said Dr. Noonberg. “I have been impressed by the company’s approach of leveraging human genetics insights and functional genomics to build an exceptional platform. I look forward to helping lead Maze’s programs through development, and ultimately, bringing them to patients in need.”

### **About Maze Therapeutics**

Maze Therapeutics is a biopharmaceutical company developing a broad portfolio of therapeutic candidates for a number of genetically defined diseases. Maze is focused on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale

human genetics data, cutting-edge functional genomics and an array of drug discovery approaches. The Maze platform reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be best targeted with drug therapies. Maze was launched in 2019 by Third Rock Ventures, with funding from ARCH Venture Partners, GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments, City Hill and other undisclosed investors. Maze is based in South San Francisco. For more information please visit [mazetx.com](http://mazetx.com).

**Media Contact**

Katie Engleman, 1AB  
[katie@1abmedia.com](mailto:katie@1abmedia.com)